The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.
BO-112 Plus Pembrolizumab Improves ORR in Advanced Melanoma After Progression on Anti–PD-1 Therapy
December 1st 2021The addition of BO-112 to pembrolizumab produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the phase 2 SPOTLIGHT-203 trial.
Experts Review Key Data From ESMO Congress 2021
November 29th 2021Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.
Practice-Changing and Reaffirming Data Set Up an Exciting Future in Melanoma
November 24th 2021Positive data readouts from studies such as the phase 2/3 RELATIVITY-047 trial with relatlimab and nivolumab, and the phase 3 KEYNOTE-716 trial with pembrolizumab, cemented 2021 as a banner year for the treatment of patients with melanoma, across various stages and subtypes.
Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma
November 23rd 2021Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.
FDA Clears IND to Expand ABILITY Trial Examining MDNA11 in Solid Tumors to the United States
November 9th 2021The FDA has greenlit an investigation new drug application to expand the ongoing phase 1/2 ABILITY trial, which is evaluating the beta-only IL-2 superagonist MDNA11 in patients with solid tumors, to clinical trial sites in the United States.
Sullivan Unpacks Breakthroughs, Challenges in the Treatment of Advanced Melanoma
November 8th 2021The addition of immune checkpoint inhibitors and targeted therapies has paved the way for advances in the adjuvant and met-astatic setting with recent data from clinical trials demonstrating significant improvements in overall survival for patients with advanced melanoma.
FDA Grants Fast Track Status to Cancer Vaccine UV1 for Advanced Malignant Melanoma
October 25th 2021The FDA has granted a fast track designation to the universal cancer vaccine UV1 for use in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma, either as an add-on therapy to pembrolizumab or to ipilimumab.
ctDNA Reduction Is Potentially Predictive of OS Vs RECIST in Metastatic Uveal Melanoma
October 4th 2021A linear correlation between magnitude of circulating tumor DNA reduction and improved overall survival was observed in patients with metastatic uveal melanoma who were treated with tebentafusp, suggesting that ctDNA may be a better surrogate end point for OS compared with RECIST response criteria.
Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA
October 1st 2021The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.
FDA Grants Priority Review to Relatlimab/Nivolumab for Unresectable or Metastatic Melanoma
September 20th 2021The FDA has granted priority review to a biologics license application for the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients aged 12 years and older and weighing at least 40 kg who have unresectable or metastatic melanoma.
UV1 Vaccine Plus Pembrolizumab Shows Strong Safety, Early Activity in Metastatic Melanoma
September 2nd 2021The universal cancer vaccine UV1 and granulocyte-macrophage colony-stimulating factor in combination with pembrolizumab elicited encouraging initial signs of clinical response with favorable safety and tolerability when used in the first-line treatment of patients with metastatic melanoma, meeting the primary end point of an ongoing phase 1 trial.
Topical Remetinostat Demonstrates Efficacy, Tolerability in Basal Cell Carcinoma
September 1st 2021The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.